Literature DB >> 8891876

Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate.

R Sorrentino1, G Cirino, A Calignano, F Mancuso, L Sorrentino, G Andriuoli, A Pinto.   

Abstract

Guinea pig aorta rings repeatedly stimulated with phenylephrine (1 microM) in the presence of Krebs solution containing ouabain (0.8 microM) or low K+ (0.5 mM) concentration produced an increase in basal tone. This effect is due to an increase in intracellular Ca2+ as a consequence of Na(+)-K+ATPase pump inhibition induced by receptorial (ouabain) or ion imbalance (low K+) mechanism. We investigated the effect of spironolactone and its metabolites canrenone and potassium canrenoate on the increase in basal tone of guinea pig aorta rings. Spironolactone, canrenone, and potassium canrenoate, in a concentration-dependent manner (3-30 microM), inhibited the increase in basal tone induced by ouabain, most likely acting as antagonist for ouabain binding site on Na(+)-K+ATPase pump. Indeed, this effect appears to be a feature of these drugs since structurally related drugs, such as aldosterone and hydrocortisone, were ineffective. Conversely, all the drugs tested reduced, to a certain degree, the increase in basal tone produced by low K+ Krebs solution, implying that this could be a non-specific effect. Our results may indicate that spironolactone, canrenone, and potassium canrenoate act in hypertension by interfering with mechanisms in which an ouabain-like factor is involved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891876     DOI: 10.1097/00005344-199610000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

2.  The negative inotropic action of canrenone is mediated by L-type calcium current blockade and reduced intracellular calcium transients.

Authors:  A R Costa; L B Torres; E Medei; R A Ricardo; J P França; S Smaili; J H M Nascimento; M E M Oshiro; J W M Bassani; A T Ferreira; P J F Tucci
Journal:  Br J Pharmacol       Date:  2009-08-06       Impact factor: 8.739

3.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.